natgillin/translations-raw huggingface dataset:
Af disse patienter havde 76% relateret diffus peritonitis (kirurgisk synlig peritonitis).
Of these patients, 76% had associated diffuse peritonitis (surgically-apparent peritonitis).
Et begrænset antal patienter med svær grundsygdom, f. eks. patienter med svækket immunforsvar, patienter med APACHE II- scorer > 15 (4%) eller multiple intraabdominale abscesser (10%), som var synlige ved kirurgisk indgreb.
There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores > 15 (4%), or with surgically apparent multiple intra-abdominal abscesses (10%).
Der foreligger også begrænset erfaring med behandling af patienter med samtidig bakteriæmi (6%).
Limited experience is also available in treating patients with concurrent bacteraemia (6%).
4. 8).
Consideration should be given to the use of combination antibacterial therapy whenever tigecycline is to be administered to severely ill patients with complicated intra-abdominal infections (cIAI) secondary to clinically apparent intestinal perforation or patients with incipient sepsis or septic shock (see section 4.8).
3 Effekten af kolestase i tigecyklins farmakokinetik er ikke fuldstændigt fastlagt.
The effect of cholestasis in the pharmacokinetics of tigecycline has not been properly established.
50% via galden.
Biliary excretion accounts for approximately 50% of the total tigecycline excretion.
4. 5).
Prothrombin time or other suitable anticoagulation test should be used to monitor patients if tigecycline is administered with anticoagulants (see section 4.5).
4. 8).
Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibacterial agent (see section 4.8).
Brugen af tigecyklin kan forårsage overvækst af ikke- følsomme organismer, herunder svampe.
The use of tigecycline may result in overgrowth of non-susceptible organisms, including fungi.
Patienterne skal derfor monitoreres nøje under behandling.
Patients should be carefully monitored during therapy.
4. 8).
If super infection occurs, appropriate measures should be taken (see section 4.8).
Resultater fra rotteforsøg med tigecyklin har påvist knoglemisfarvning.
Results of studies in rats with tigecycline have shown bone discolouration.
4. 8).
Tigecycline may be associated with permanent tooth discolouration in humans if used during tooth development (see section 4.8).
4. 8).
Tygacil should not be used in children under 8 years of age because of teeth discolouration, and is not recommended in adolescents below 18 years due to the lack of data on safety and efficacy (see sections 4.2 and 4.8).
Samtidig administration af tigecyklin og warfarin (enkeltdosis på 25 mg) til raske forsøgspersoner viste et fald i clearance af R- warfarin og S- warfarin på 40% og 23% og en stigning i AUC på henholdvis 68% og 29%.
Concomitant administration of tigecycline and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40% and 23%, and an increase in AUC by 68% and 29%, respectively.
Men eftersom tigecyklin muligvis forlænger både protrombintiden (PT) og den aktiverede partielle tromboplastintid (aPTT), skal de relevante koagulationstest monitoreres nøje, når tigecyklin administreres samtidigt med antikoagulantia (se pkt.
However, since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants (see section 4.4).
Warfarin påvirkede ikke tigecyklins farmakokinetiske profil.
Warfarin did not affect the pharmacokinetic profile of tigecycline.
Tigecyklin metaboliseres ikke udtalt.
4 Tigecycline is not extensively metabolised.
Tigecyklins clearance forventes derfor ikke at blive påvirket af aktive stoffer, som hæmmer eller inducerer aktiviteten af disse CYP450 isoformer (se pkt.
Therefore, clearance of tigecycline is not expected to be affected by active substances that inhibit or induce the activity of the CYP450 isoforms.
5. 2 Farmakokinetiske egenskaber).
In vitro, tigecycline is neither a competitive inhibitor nor an irreversible inhibitor of CYP450 enzymes (see section 5.2).
Den anbefalede tigecyklin- dosis påvirkede ikke hastigheden eller omfanget af absorptionen og heller ikke clearance af digoxin (0, 5 mg efterfulgt af 0, 25 mg dagligt), når lægemidlet blev administreret til raske voksne.
Tigecycline in recommended dosage did not affect the rate or extent of absorption, or clearance of digoxin (0.5 mg followed by 0.25 mg daily) when administered in healthy adults.
Digoxin påvirkede ikke tigecyklins farmakokinetiske profil.
Digoxin did not affect the pharmacokinetic profile of tigecycline.
Det er derfor ikke nødvendigt at foretage dosisjustering, når tigecyklin administreres samtidigt med digoxin.
Therefore, no dosage adjustment is necessary when tigecycline is administered with digoxin.
Der er ikke påvist antagonisme i in- vitro forsøg mellem tigecyklin og andre almindeligt anvendte antibiotikagrupper.
In in vitro studies, no antagonism has been observed between tigecycline and other commonly used antibiotic classes.
Der foreligger ingen erfaring med anvendelsen af tigecyklin til gravide.
There are no adequate data from the use of tigecycline in pregnant women.
(Se
Results from animal studies have shown tigecycline may cause foetal harm when administered during pregnancy (see section 5.3).
4. 4).
As it is known for tetracycline class antibiotics, tigecycline may also induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses, exposed in utero during the last half of gestation, and in children under eight years of age due to the enrichment in tissues with a high calcium turnover and formation of calcium chelate complexes (see section 4.4).
Tigecyklin må kun anvendes på tvingende indikation under graviditet.
Tigecycline should not be used during pregnancy unless clearly necessary.
Det vides ikke om dette lægemiddel udskilles i modermælk.
It is not known whether this medicinal product is excreted in human milk.
I dyreforsøg udskilles tigecyklin i diegivende rotters mælk.
In animal studies tigecycline is excreted into milk of lactating rats.
5. 3).
Because a potential risk to the breast-feeding infant cannot be ruled out, when treating with tigecycline, caution should be exercised and interruption of breast-feeding should be considered (see section 5.3).
Der er ikke foretaget undersøgelser af tigecyklins virkning på evnen til at føre motorkøretøj eller betjene maskiner.
No studies on the effects of tigecycline on the ability to drive and use machines have been performed.
4. 8).
Dizziness may occur and this may have an effect on driving and use of machines (see section 4.8).
Der blev rapporteret om bivirkninger hos ca.
The total number of patients treated with tigecycline in Phase 3 clinical studies was 1415.
41% af de patienter, som blev behandlet med tigecyklin.
Adverse reactions were reported in approximately 41% of patients treated with tigecycline.
Behandlingen blev seponeret hos 5% af patienterne på grund af bivirkninger.
Treatment was discontinued due to adverse reactions in 5% of patients.
De mest almindelige bivirkninger, opstået under behandling, i kliniske forsøg var reversibel kvalme (20%) og opkastning (14%), som ofte viste sig tidligt (på 1. - 2. behandlingsdag) og som generelt var milde eller moderate i sværhedsgrad.
In clinical trials, the most common drug-related treatment emergent adverse reactions were reversible nausea (20%) and vomiting (14%), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity.
Neden for oplistes bivirkninger indberettet på Tygacil fra både kliniske undersøgelser og efter markedsføring:
Adverse reactions reported with Tygacil, including clinical trials and post-marketing experience, are listed below:
Hyppigheden udtrykkes i følgende kategorier:
Frequency categories are expressed as:
Meget almindelig (≥ 1/ 10), Almindelig (≥ 1/ 100 - < 1/ 10), Usædvanlig (≥ 1/ 1. 000 - < 1/ 100), Sjælden (≥ 1/ 10. 000 - < 1/ 1. 000), Meget sjælden (< 1/ 10. 000).
Very common (≥ 1/ 10); Common (≥ 1/ 100 to < 1/ 10); Uncommon (≥ 1/ 1,000 to < 1/ 100); Rare (≥ 1/ 10,000 to < 1/ 1,000); Very Rare (< 1/ 10,000)
For bivirkninger observeret efter markedsføring af Tygacil, indberettet som spontane rapporter, hvor hyppigheden ikke kan beregnes, er hyppigheden kategoriseret som ukendt.
5 For adverse reactions identified from post-marketing experience with Tygacil derived from spontaneous reports for which the frequency cannot be estimated, the frequency grouping is categorized as not known.
Absces, infektioner Usædvanlig:
Abscess, infections Uncommon:
Sepsis/ septisk shock
Sepsis/ septic shock
I kliniske fase III- forsøg blev der oftere rapporteret om infektionsrelaterede, alvorlige bivirkninger hos forsøgspersoner, som blev behandlet med tigecyklin (6, 7%) i forhold til komparatorer (4, 6%).
In Phase 3 clinical studies, infection-related serious adverse events were more frequently reported for subjects treated with tigecycline (6.7%) vs comparators (4.6%).
Der blev observeret signifikante forskelle i sepsis/ septisk shock med tigecyklin (1, 5%) i forhold til komparatorer (0, 5%).
Significant differences in sepsis/ septic shock with tigecycline (1.5%) vs comparators (0.5%) were observed.
Sygdomme i blod - og lymfesystem:
Blood and the lymphatic system disorders:
Usædvanlig:
Prolonged activated partial thromboplastin time (aPTT), Prolonged prothrombin time (PT) Uncommon:
Trombocytopeni
Increased International Normalised Ratio (INR) Not known: thrombocytopenia
4. 3 og 4. 4)
Anaphylaxis/ anaphylactoid reactions (see sections 4.3 and 4.4)
Hypoproteinæmi 5 Sygdomme i nervesystemet:
Nervous system disorders:
Flebitis Usædvanlig:
Phlebitis Uncommon:
Almindelig:
Nausea, vomiting, diarrhoea Common:
Abdominalsmerter, dyspepsi, anoreksi Usædvanlig:
Abdominal pain, dyspepsia, anorexia Uncommon:
Sygdomme i lever og galdeveje:
Hepato-biliary disorders:
Forhøjet aspartat aminotransferase (ASAT) i serum, forhøjet alanin aminotransferase (ALAT) i serum, hyperbilirubinæmi
Elevated aspartate aminotransferase (AST) in serum, and elevated alanine aminotransferase (ALT) in serum, hyperbilirubinaemia
Der blev oftere rapporteret om anormale ASAT - og ALAT- værdier hos Tygacil- behandlede patienter i perioden efter behandling end hos de patienter, som blev behandlet med komparator, hvilket oftere fandt sted under behandling.
AST and ALT abnormalities in Tygacil-treated patients were reported more frequently in the post therapy period than in those in comparator-treated patients, which occurred more often on therapy.
Gulsot, leverskade – oftest cholestatisk
Jaundice, liver injury, mostly cholestatic
Sygdomme i hud og subkutane væv:
6 Skin and subcutaneous tissue disorders:
Pruritus, udslæt.
Pruritus, rash
Ikke almindelig:
Headache Uncommon:
Reaktion ved injektionsstedet, betændelse ved injektionsstedet, smerte ved injektionsstedet, ødem ved injektionsstedet, flebitis ved injektionsstedet.
Injection site reaction, injection site inflammation, injection site pain, injection site oedema, injection site phlebitis
Forhøjet amylase i serum, øget urinkvælstof (BUN)
Elevated amylase in serum, increased blood urea nitrogen (BUN)
I Fase 3 cSSSI - og cIAI- forsøg døde 2, 3% (32 ud af 1. 383) af de patienter, som fik tigecyklin, og 1, 6% (22 ud af 1. 375) af de patienter, som modtog komparator.
In Phase 3 cSSSI and cIAI studies, death occurred in 2.3% (32/ 1383) of patients receiving tigecycline and 1.6% (22/ 1375) of patients receiving comparator drugs.
Bivirkninger ved antibiotikaklassen:
Antibiotic Class Effects:
4. 4).
Pseudomembranous colitis which may range in severity from mild to life threatening (see section 4.4)
4. 4).
Overgrowth of non-susceptible organisms, including fungi (see section 4.4)
Bivirkninger ved tetracyklinklassen:
Tetracycline Class Effects:
4. 4).
Tetracycline class adverse reactions may include photosensitivity, pseudotumour cerebri, pancreatitis, and anti-anabolic action which has led to increased BUN, azotaemia, acidosis, and hyperphosphataemia (see section 4.4).
4. 4).
Tigecycline may be associated with permanent tooth discolouration if used during tooth development (see section 4.4).
Intravenøs administration af tigecyklin ved en enkelt dosis på 300 mg i løbet af 60 minutter hos raske frivillige resulterede i en øget forekomst af kvalme og opkastning.
Intravenous administration of tigecycline at a single dose of 300 mg over 60 minutes in healthy volunteers resulted in an increased incidence of nausea and vomiting.
Tigecyklin fjernes ikke i signifikante mængder ved hæmodialyse.
Tigecycline is not removed in significant quantities by haemodialysis.
Tetracycliner, ATC- kode:
Tetracyclines, ATC code:
Virkningsmåde Tigecyklin, som er et glycylcyklinantibiotikum, hæmmer proteintranslation i bakterier ved at binde sig til den 30S- ribosomale subenhed og blokere tilførslen af amino- acyl- tRNA- molekyler til ribosomets A- site.
Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome.
Dette forhindrer inkorporeringen af aminosyre- rester i forlængede peptidkæder.
This prevents incorporation of amino acid residues into elongating peptide chains.
Generelt betragtes tigecyklin som bakteriostatisk.
7 In general, tigecycline is considered bacteriostatic.
Ved 4 gange den mindste hæmmende koncentration (MIC) blev der observeret en 2- log- reduktion i kolonitællinger med tigecyklin til behandling af Enterococcus spp., Staphylococcus aureus og Escherichia coli.
At 4 times the minimum inhibitory concentration (MIC), a 2-log reduction in colony counts was observed with tigecycline against Enterococcus spp., Staphylococcus aureus, and Escherichia coli.
Resistensmekanisme Tigecyklin påvirkes ikke af de to store tetracyklinresistensmekanismer, ribosomal beskyttelse og effluks.
Tigecycline is able to overcome the two major tetracycline resistance mechanisms, ribosomal protection and efflux.
Det er imidlertid sårbart over for kromosomalt indkodede multistof efflukspumper for Proteeae (se nedenfor) og Pseudomonas aeruginosa (MexXY- OprM efflukssystem).
However, it is vulnerable to chromosomally-encoded multidrug efflux pumps of Proteeae (see below) and Pseudomonas aeruginosa (MexXY-OprM efflux system).
Der er ingen målbaseret krydsresistens mellem tigecyklin og de fleste antibiotikaklasser.
There is no target-based cross-resistance between tigecycline and most classes of antibiotics.
Patogener i Proteeae- gruppen (Proteus spp., Providencia spp. og Morganella spp.) er generelt mindre følsomme over for tigecyklin end andre medlemmer af Enterobacteriaceae.
Pathogens of the family Proteeae (Proteus spp., Providencia spp., and Morganella spp.) are generally less susceptible to tigecycline than other members of the Enterobacteriaceae.
Derudover er der registreret nogen erhvervet resistens over for Klebsiella pneumoniae, Enterobacter aerogenes og Enterobacter cloacae.
In addition, some acquired resistance has been detected in Klebsiella pneumoniae, Enterobacter aerogenes, and Enterobacter cloacae.
Den nedsatte følsomhed i begge grupper er blevet tilskrevet overekspression af den ikke- specifikke AcrAB- efflukspumpe til flere lægemidler.
Decreased susceptibility in both groups has been attributed to the overexpression of the non-specific AcrAB multi-drug efflux pump.
Breakpoints Breakpoints for mindste hæmmende koncentration (MIC) fastlagt af European Committee on Antimicrobial Susceptibility Testing (EUCAST) er som følger:
Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:
Pneumoniae Følsom ≤ 0, 25 mg/ l og Resistent > 0, 5 mg/ l.
S ≤ 0.5 mg/ L and R > 0.5 mg/ L Streptococcus spp. other than S. pneumoniae S ≤ 0.25 mg/ L and R > 0.5 mg/ L Enterococcus spp.
Følsom ≤ 0, 25 mg/ l og Resistent > 0, 5 mg/ l Enterobacteriaceae Følsom ≤ 1( ^) mg/ l og Resistent > 2 mg/ l () ^ Tigecyklin har nedsat in vitro aktivitet over for Proteus, Providencia og Morganella spp.
S ≤ 0.25 mg/ L and R > 0.5 mg/ L Enterobacteriaceae S ≤ 1(^) mg/ L and R > 2 mg/ L (^) Tigecycline has decreased in vitro activity against Proteus, Providencia, and Morganella spp.
For anærobe bakterier er der klinisk evidens for effekt over for polymikrobiale intra- abdominale infektioner men ingen korrelation mellem MIC værdier, PK/ PD data og klinisk resultat.
For anaerobic bacteria there is clinical evidence of efficacy in polymicrobial intra-abdominal infections, but no correlation between MIC values, PK/ PD data and clinical outcome.
Det skal noteres, at MIC fordelingen for organismer af arterne bakteroider og Clostridium er bred og kan inkludere værdier over 2mg/ l tigecyklin.
It should be noted that the MIC distributions for organisms of the genera Bacteroides and Clostridium are wide and may include values in excess of 2 mg/ L tigecycline.
Der er begrænset evidens for klinisk effekt af tigecyklin over for enterokokker.
There is limited evidence of the clinical efficacy of tigecycline against enterococci.
Polymikrobiale intra - abdominale infektioner har dog responderet på behandling med tigecyklin i kliniske undersøgelser.
However, polymicrobial intra-abdominal infections have shown to respond to treatment with tigecycline in clinical trials.
Følsomhed Forekomsten af erhvervet resistens kan variere geografisk og tidsmæssigt for valgte arter, og lokale oplysninger om resistens er ønskelig især ved behandling af svære infektioner.
The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections.
7 Almindeligt følsomme arter Enterococcus spp. † Staphylococcus aureus * Staphylococcus epidermidis Staphylococcus haemolyticus Streptococcus agalactiae * Streptococcus anginosus gruppen. * (herunder S. anginosus, S. intermedius and S. constellatus) Streptococcus pyogenes * Streptokokker i viridansgruppen Citrobacter freundii * Citrobacter koseri Enterobacter aerogenes Enterobacter cloacae * Escherichia coli * Klebsiella oxytoca * Klebsiella pneumoniae * Serratia marcescens Clostridium perfringens † Peptostreptococcus spp. † Prevotella spp.
Staphylococcus haemolyticus Streptococcus agalactiae* Streptococcus anginosus group* (includes S. anginosus, S. intermedius and S. constellatus) Streptococcus pyogenes* Viridans group streptococci Citrobacter freundii* Citrobacter koseri Enterobacter aerogenes Enterobacter cloacae* Escherichia coli* Klebsiella oxytoca* Klebsiella pneumoniae* Serratia marcescens Clostridium perfringens† Peptostreptococcus spp .† Prevotella spp.
Arter hvor erhvervet resistens kan være et problem Acinetobacter baumannii Bacteroides fragilis gruppen † Burkholderia cepacia Morganella morganii Providencia spp Proteus spp.
Proteus spp.
Medfødt resistente organismer Pseudomonas aeruginosa * Betegner arter mod hvilke det anses, at aktitivitet er tilfredsstillende påvist i kliniske studier † Se afsnit 5. 1, Breakpoints, ovenfor
Inherently resistant organisms Pseudomonas aeruginosa * denotes species against which it is considered that activity has been satisfactorily demonstrated in clinical studies. † see section 5.1, Breakpoints above.
Absorption Tigecyklin administreres intravenøst og har derfor en biotilgængelighed på 100%.
Tigecycline is administered intravenously and therefore has 100% bioavailability.
71% til 89% ved koncentrationer, som blev observeret i kliniske forsøg (0, 1- 1, 0 µg/ ml).
The in vitro plasma protein binding of tigecycline ranges from approximately 71% to 89% at concentrations observed in clinical studies (0.1 to 1.0 µg/ ml).
Farmakokinetiske forsøg med dyr og mennesker har påvist, at tigecyklin nemt fordeles i væv.
Animal and human pharmacokinetic studies have demonstrated that tigecycline readily distributes to tissues.
Hos rotter, som fik en enkelt eller flere doser af 14C- tigecyklin, blev radioaktiviteten fordelt godt i de fleste væv, hvor den højeste overordnede eksponering blev observeret i knoglemarv, spytkirtler, skjoldbruskkirtlen, milten og nyrerne.
In rats receiving single or multiple doses of 14C-tigecycline, radioactivity was well distributed to most tissues, with the highest overall exposure observed in bone marrow, salivary glands, thyroid gland, spleen, and kidney.
Hos mennesker lå tigecyklins gennemsnitlige distributionsvolumen ved steady- state på 500- 700 l (7- 9 l/ kg), hvilket angiver, at tigecyklin fordeles i stort omfang ud over plasmavolumen og koncentreres i væv.
In humans, the steady-state volume of distribution of tigecycline averaged 500 to 700 L (7 to 9 L/ kg), indicating that tigecycline is extensively distributed beyond the plasma volume and concentrates into tissues.
Der foreligger ingen data om, hvorvidt tigecyklin kan krydse blodhjernebarrieren hos mennesker.
9 No data are available on whether tigecycline can cross the blood-brain barrier in humans.
I kliniske, farmakologiske undersøgelser med anvendelse af det terapeutiske dosisregime på 100 mg fulgt af 50 mg/ 12 timer var serum tigecyklin steady- state Cmax 866±233 ng/ ml for 30 minutters infusioner og 634±97 ng/ ml for 60 minutters infusioner.
In clinical pharmacology studies using the therapeutic dosage regimen of 100 mg followed by 50 mg q12h, serum tigecycline steady-state Cmax was 866±233 ng/ ml for 30-minute infusions and 634±97 ng/ ml for 60-minute infusions.
Steady- state AUC0- 12 t var 2349±850 ng• t/ ml.
The steady-state AUC0-12h was 2349±850 ng• h/ ml.
8 Metabolisme Det vurderes, at mindre end 20% af tigecyklin i gennemsnit metaboliseres før udskillelse.
On average, it is estimated that less than 20% of tigecycline is metabolised before excretion.
Hos raske frivillige mænd var uændret tigecyklin det primære 14C- mærkede materiale, som blev genfundet i urin og fæces efter administration af 14C- tigecyklin, men en glukoronid, en N- acetylmetabolit og en tigecyclin epimer var også til stede.
In healthy male volunteers, following the administration of 14C-tigecycline, unchanged tigecycline was the primary 14 C-labelled material recovered in urine and faeces, but a glucuronide, an N-acetyl metabolite and a tigecycline epimer were also present.
In- vitro studier i humane levermikrosomer indikerer, at tigecyklin ikke hæmmer metaboliseringen medieret af nogle af følgende 6 cytokrom P450 (CYP) isoformer:
In vitro studies in human liver microsomes indicate that tigecycline does not inhibit metabolism mediated by any of the following 6 cytochrome P450 (CYP) isoforms:
1A2, 2C8, 2C9, 2C19, 2D6 og 3A4 ved kompetitiv hæmning.
1A2, 2C8, 2C9, 2C19, 2D6, and 3A4 by competitive inhibition.
Derudover viste tigecyklin ingen NADPH- afhængighed ved hæmning af CYP2C9, CYP2C19, CYP2D6 og CYP3A, hvilket tyder på, at der ikke er nogen mekanismebaseret hæmning af disse CYP enzymer.
In addition, tigecycline did not show NADPH-dependency in the inhibition of CYP2C9, CYP2C19, CYP2D6 and CYP3A, suggesting the absence of mechanism-based inhibition of these CYP enzymes.
Elimination Genfundet af total radioaktivitet i fæces og urin, efter administration af 14C- tigecyklin, angiver, at 59% af dosis elimineres via galden og fæces, og 33% udskilles via urin.
The recovery of the total radioactivity in faeces and urine following administration of 14C-tigecycline indicates that 59% of the dose is eliminated by biliary/ faecal excretion, and 33% is excreted in urine.
Generelt er tigecyklins primære eliminationsvej galden til udskillelse af uændret tigecyklin.
Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline.
Glukuronidering og renal udskillelse af uændret tigecyklin er de sekundære veje.
Glucuronidation and renal excretion of unchanged tigecycline are secondary routes.
Tigecyklins samlede clearance er 24 l/ t. efter intravenøs infusion.
The total clearance of tigecycline is 24 L/ h after intravenous infusion.
13% af den samlede clearance.
Renal clearance is approximately 13% of total clearance.